Skip to content

Simvastatin Gel With Perforated Resorbable Membranes in Treatment of Intrabony Defects in Chronic Periodontitis

The Use of Simvastatin Gel With Perforated Resorbable Membranes in the Treatment of Intrabony Defects in Chronic Periodontitis Patients (Clinical and Biochemical Study)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03419429
Enrollment
40
Registered
2018-02-05
Start date
2016-01-31
Completion date
2017-06-30
Last updated
2018-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Keywords

Guided tissue membranes, EDTA, Simvastatin

Brief summary

Modified perforated membrane (MPM) is considered as a modality that could enable participation of periosteal cells and gingival stem cells which could improve the outcomes of guided tissue regeneration more than the use of the traditional occlusive membrane (OM). Simvastatin (SMV) modulates bone formation by increasing the expression of bone morphogenetic protein 2 and angiogenesis. Ethylenediaminetetraacitic acid (EDTA) found to be effective as low ph etchant for smear layer removal and exposing root surface collagen. The investigators compared the clinical and radiographic outcome of SMV gel combined with MPM to SMV gel combined with OM with and without an associated EDTA gel root surface etching for improving bone regeneration in intrabony defects in chronic periodontitis patients. Moreover, evaluation of SMV gingival crevicular fluid (GCF) levels availability for 30 days in cases with and without EDTA root surface etching was performed.

Detailed description

Forty patients with 40 intrabony defects having chronic periodontitis were randomly assigned into four equal groups to receive open flap procedure, 1.2% SMV gel and covering the defect with OM (Group I), open flap procedure, 1.2% SMV gel and covering the defect with MPM (Group II), open flap procedure, 24% EDTA root surface etching,1.2% SMV gel and then coverage of the defect by OM (Goup III), or open flap procedure, 24% EDTA root surface etching, 1.2% SMV gel and then coverage of the defect by MPM (Group IV). Plaque index, gingival index,probing pocket depth, clinical attachment level, defect base level, crestal bone level, and radiodensitometric measurements were measured at baseline and reassessed at 6 and 9 months after therapy. Additionally, GCF was collected from group I, II, III and IV at 1,7,14, 21, and 30 days in order to evaluate SMV availability and the effect of EDTA root surface etching on its availability using High-performance liquid chromatography(HPLC).

Interventions

DRUGSimvastatin

Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.

OTHEREDTA

EDTA is a demineralizing agent used for root surface conditioning.

Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.

DEVICEModified perforated membrane

Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patients were all healthy and free from any systemic disease. * No history of antibiotic therapy or periodontal treatment for at least six months preceding the study. * Patients were willing and able to return for multiple follow up visits. * Periodontal defects with 1. Probing depth \> 5 mm. 2. Clinical attachment loss \>4 mm. 3. Standardized radiographic evidence of interproximal intrabony defect using periapical radiograph. * Good level of oral hygiene (plaque and gingival indices score after initial phase therapy should be less than one).

Exclusion criteria

* Pregnancy, lactation for female patients. * Smokers, alcoholics and those receiving any medication that could affect healing of soft tissue and bone as steroids and cyclosporines. * History of allergic reaction to the medications used. * Vulnerable groups and handicapped.

Design outcomes

Primary

MeasureTime frameDescription
Plaque indexBaseline to 9 monthsPlaque index was measured from baseline to 6 months and 9 months
Probing pocket depthBaseline to 9 monthsProbing pocket depth was measured from the free gingival margin to the base of the pocket from baseline to 6 months and 9 months
Clinical attachment levelBaseline to 9 monthsClinical attachment level was measured from the cementoenamel junction to the base of the pocket from baseline to 6 months and 9 months
Radiodensitometric measurementsBaseline to 9 monthsBone density was measured using Digora software from baseline to 6 months and 9 months
Gingival indexBaseline to 9 monthsGingival index was measured from baseline to 6 months and 9 months
Linear measurementsBaseline to 9 monthsLinear measurements were measured using Digora software from baseline to 6 months and 9 months

Secondary

MeasureTime frameDescription
Simvastatin gingival crevicular fluid levelsDay 1, 7, 14, 21 and 30Simvastatin gingival crevicular fluid levels availability in cases with and without EDTA root surface etching using HPLC at day 1, 7, 14, 21,and 30

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026